New biomarker data from BEXMAB study at EHA2023 : vimarsana.

Faron Pharmaceuticals Oy  
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress
Bexmarilimab mode of action in AML/MDS supported with durable Clever-1... | June 9, 2023

Related Keywords

Boston , Massachusetts , United States , Jukka , Lapland , Finland , Juha Karttunen , Sandy Jamieson , Jo Turner , Christopher Golden , Lindsey Neville , Jenniferc Smith Parker , Julia Balanova , David Daley , Head Of Communications , Prnewswire Faron Pharmaceuticals Oy , Congress On , Faron Pharmaceuticals Oy , Peel Hunt , Cairn Financial Advisers , Faron Pharmaceuticals , European Hematology Association , Consilium Strategic Communications , Announces New Biomarker Data , First North , Chief Medical Officer , Certified Adviser , Nasdaq First , Faro Technologies , Nc Stock Exchange , News , Information , Press Release , Aaron , Pharmaceuticals , Nnounces , Few , Biomarker , Data , Rom , Hase , Exmab , Study , It , Ha2023 , Hybrid , Mode , F , Action , N , Upported , Ith , Urable Faro Us3116421021 ,